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DOI 10.1016/j.ccr.2011.02.014SUMMARYTumor cells exhibit aberrant metabolism characterized by high glycolysis even in the presence of oxygen.
This metabolic reprogramming, known as the Warburg effect, provides tumor cells with the substrates
required for biomass generation. Here, we show that the mitochondrial NAD-dependent deacetylase
SIRT3 is a crucial regulator of theWarburg effect. Mechanistically, SIRT3mediatesmetabolic reprogramming
by destabilizing hypoxia-inducible factor-1a (HIF1a), a transcription factor that controls glycolytic gene
expression. SIRT3 loss increases reactive oxygen species production, leading to HIF1a stabilization.
SIRT3 expression is reduced in human breast cancers, and its loss correlates with the upregulation of
HIF1a target genes. Finally, we find that SIRT3 overexpression represses glycolysis and proliferation in
breast cancer cells, providing a metabolic mechanism for tumor suppression.INTRODUCTION
Otto Warburg first noted in the 1920s that cancer cells undergo
glycolysis even in the presence of ample oxygen (Warburg,
1956). This preferential use of aerobic glycolysis, termed the
Warburg effect, has emerged as a metabolic hallmark of many
cancers. As a result, there is much interest in understanding
the pathways that regulate the potential survival and proliferative
advantages conferred by increased glucose uptake and catabo-
lism, and this topic has been extensively reviewed (Tennant
et al., 2010; Vander Heiden et al., 2009). Accruing evidence
suggests that aerobic glycolysis is used to support the rapidSignificance
The dysregulation of cell metabolism is a unique and defining
regulate cancer cell metabolism will enhance our understandin
and provide approaches for cancer therapy. We find that loss o
stabilizes HIF1a and shifts cellular metabolism toward increas
Importantly, we also show that SIRT3 overexpression repres
SIRT3 deletion in human cancers and suggest that SIRT3 may
416 Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc.proliferation of tumor cells. Enhanced catabolism of glucose
contributes to the raw materials needed to synthesize the nucle-
otides, amino acids, and lipids necessary for cellular proliferation
and can provide a distinct growth advantage for cells with
elevated aerobic glycolysis (Tong et al., 2009). Constitutive upre-
gulation of aerobic glycolysis can also provide a survival advan-
tage for tumor cells because limitations in tumor vascularization
result in periods of intermittent hypoxia that require a cell to rely
on glycolysis (Gatenby and Gillies, 2004). In support of this
notion, the transition from premalignant lesions to invasive
cancer is often accompanied by increased tumor glucose uptake
(Gatenby and Gillies, 2004).feature of many tumor cells. Thus, identifying factors that
g of how tumors hijack metabolism for selective advantages
f SIRT3, a sirtuin with NAD-dependent deacetylase activity,
ed glycolysis, a common metabolic switch in cancer cells.
ses the Warburg effect. Our studies identify a high rate of
be an important therapeutic target.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1aMetabolic reprogramming in cancer cells is regulated by
several oncogenic cues, including the PI3K/Akt, Myc, or
hypoxia-inducible factor (HIF) pathways that serve to increase
glucose uptake, glycolysis, angiogenesis, and stress resistance
(Kaelin and Ratcliffe, 2008; Semenza, 2010; Tennant et al., 2010;
Tong et al., 2009). Recently, mutations in mitochondrial enzymes
have emerged as important drivers of altered tumor cell metab-
olism. For example, gain- or loss-of-function mutations in tricar-
boxylic acid (TCA) cycle enzymes regulate HIF1 activity and
promote carcinogenesis (Gottlieb and Tomlinson, 2005; Zhao
et al., 2009). In turn, identification of new mitochondrial regula-
tors of global cellular reprogramming could provide important
insight into the contribution of altered metabolism to
tumorigenesis.
Sirtuins are a conserved family of NAD-dependent ADP-ribo-
syltransferases and/or protein deacetylases involved in metabo-
lism, stress response, and longevity (Finkel et al., 2009).
Mammals express seven sirtuins (SIRT1–7), three of which
(SIRT3–5) are localized to the mitochondrion. SIRT3 is a major
mitochondrial deacetylase that targets many enzymes involved
in central metabolism, resulting in the activation of many oxida-
tive pathways (Verdin et al., 2010). For example, SIRT3 deacety-
lates complex I and complex II to activate electron transport (Ahn
et al., 2008; Cimen et al., 2010). SIRT3 induces fatty acid oxida-
tion during fasting in hepatocytes via deacetylation of LCAD
(Hirschey et al., 2010). SIRT3 also targets the mitochondrial
enzymes IDH2 and MnSOD (Qiu et al., 2010; Schlicker et al.,
2008; Someya et al., 2010; Tao et al., 2010), which function in
part to maintain reactive oxygen species (ROS) homeostasis.
SIRT3 loss increases ROS levels and contributes to numerous
age-related pathologies, including hearing loss and tumorigen-
esis (Kim et al., 2010; Someya et al., 2010). Previously, it was
shown that SIRT3 functions as a tumor suppressor by
decreasing ROS and maintaining genomic stability (Kim et al.,
2010). In this study it was also demonstrated that SIRT3 null cells
display increased glucose uptake and altered mitochondrial
oxidation, but the direct contribution of SIRT3-mediated meta-
bolic regulation on tumor growth remains a central question.
Due to the pivotal role of SIRT3 as a regulator of ROS and
multiple mitochondrial pathways, we sought to specifically
probe the role of SIRT3 in regulating tumor cell metabolism
and growth.
RESULTS
SIRT3 Promotes Cellular Metabolic Reprogramming
Because SIRT3 activates enzymes involved in mitochondrial fuel
catabolism (Verdin et al., 2010), and SIRT3 loss increases
glucose uptake (Kim et al., 2010), we hypothesized that SIRT3
could serve as an important regulator of the balance between
glycolytic and anabolic pathways and mitochondrial oxidative
metabolism to regulate tumor cell growth. To test this idea we
first examined the influence of SIRT3 loss on metabolites from
mouse embryonic fibroblasts (MEFs) using liquid chromatog-
raphy-mass spectrometry (LC-MS). The metabolic profile of
SIRT3 null (KO) MEFs demonstrated a clear shift toward glyco-
lytic metabolism when compared with SIRT3 wild-type (WT)
counterparts (Figure 1A), similar to the metabolic shift reported
for transformed cells in culture (Lu et al., 2010) and for cancercells in vivo (Denkert et al., 2008; Hirayama et al., 2009). In
SIRT3 KO cells, intermediates of glycolysis were elevated,
whereas TCA cycle metabolites were reduced (Figures 1B and
1C). Consistent with a pattern of increased glucose usage,
SIRT3 KO cells had lower levels of intracellular glucose (Fig-
ure 1D), whereas levels of glucose-1-phosphate, a product of
glycogenolysis, were increased (Figure 1E). Glucose-1-phos-
phate can be converted by phosphoglucomutase into glucose-
6-phosphate (G6P) to provide substrates for glycolysis or the
oxidative arm of the pentose phosphate pathway (PPP), gener-
ating NADPH and ribose. The nonoxidative arm of the PPP forms
ribose-5-phosphate from fructose-6-phosphate or glyceralde-
hyde-3-phosphate (Figure 1A). Importantly, G6P, glycolytic
intermediates, and ribose-5-phosphate were all increased in
SIRT3 KO cells (Figures 1A and 1F), suggesting that glucose
metabolites were diverted into the PPP in order to provide the
ribose necessary for nucleic acid synthesis. Notably, the pattern
and the magnitude of metabolomic changes caused by SIRT3
loss were similar to those observed comparing tumors to nearby
normal tissue (Hirayama et al., 2009).
Increased metabolites involved in glycolysis and the PPP sug-
gested that, like many cancer cells, SIRT3 KO MEFs might be
using glucose to support increased proliferation by directing
glucose away from the TCA cycle toward biosynthetic
processes. Indeed, SIRT3 KO cells grew significantly faster
than WT cells (Figure 1G). To test whether this increased growth
rate required aerobic metabolism of glucose, we grew cells in
media containing galactose instead of glucose, thereby reducing
glycolytic flux and forcing the cell to rely on mitochondrial oxida-
tive phosphorylation (Marroquin et al., 2007). Under these condi-
tions,WT and KO cells grew at the same rate, demonstrating that
the increased proliferation of KO cells required enhanced
glucose catabolism (Figure 1H).
To confirm that themetabolite patterns reflected an increase in
glycolysis, we measured glucose uptake and lactate production.
As expected, SIRT3 KO MEFs consumed more glucose and
extruded more lactate into the media than did WT cells (Figures
1I and 1J). This effect was not specific toMEFs; HEK293T cells in
which SIRT3 expression was stably reduced by lentiviral expres-
sion of shRNA against SIRT3 also showed an increase in glucose
uptake and lactate production (see Figures S1A and S1B avail-
able online). Interestingly, the effect of SIRT3 loss on glucose
uptake and lactate production was similar to the effect of pyru-
vate kinase M2 isoform overexpression or mTOR activation
(Christofk et al., 2008; Duvel et al., 2010). These data suggest
that loss of SIRT3 redirects cellular metabolism in favor of glycol-
ysis, and as a result, cells with low levels of SIRT3 display
features similar to the Warburg effect apparent in many cancer
cells.
Previous studies have found that SIRT3 loss increases
glucose uptake (Kim et al., 2010), yet, to our knowledge,
the specific mechanism involved has not been elucidated. To
test whether SIRT3 upregulates glycolysis as part of a compen-
satory response due to diminished oxidative capacity, we
examined glucose uptake and lactic acid secretion in the
presence of a mitochondrial respiratory inhibitor, rotenone, or
an inhibitor of mitochondrial fatty acid oxidation, etomoxir. In
WT cells, glycolysis is increased in the presence of both rote-
none (Figures 1K and 1L) and etomoxir (Figures 1M and 1N).Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc. 417
BF
SIRT3 WT SIRT3 KO
0.0
0.5
1.0
1.5
2.0
**
D
SIRT3 WT SIRT3 KO
0.0
0.5
1.0
1.5
**
F1
6D
P/F
26D
P/G
16D
P
DH
AP
3-p
hos
pho
gly
cer
ate
2-p
hos
pho
gly
cer
ate PE
P
0.0
0.5
1.0
1.5
2.0
2.5 SIRT3 WT
SIRT3 KO
**
** *
R
el
at
iv
e 
le
ve
ls
 
glucose
(glucose-6-phosphate)
(fructose-6-phosphate)
fructose-1,6-bisphosphate
(1,3-bisphosphoglycerate)
3-phosphoglycerate
2-phosphoglycerate
phosphoenolpyruvate
pyruvate lactate
ribose-5-phosphate
(3-phosphoglyceraldehyde)dihydroxyacetonephosphate
(acetyl-CoA)
oxaloacetate
malate
fumarate
succinate
(succinyl-CoA)
α-ketoglutarate
isocitrate
citrate
aconitate
PPP
extracellular
A
SIRT3 WT
SIRT3 KO
pyr
uva
te
citr
ate
aco
nita
te
iso
citr
ate
alp
ha-
ket
ogl
uta
rate
suc
cin
ate
/me
thy
lma
lon
ate
fum
ara
te
ma
late
oxa
loa
cet
ate
0.0
0.5
1.0
1.5
**
**
*
**
R
el
at
iv
e 
le
ve
ls
 
C
J
0 1 2 3 4
0.5
1.0
1.5
2.0
SIRT3 WT
SIRT3 KO
***
Day
C
el
l n
um
be
r (
x 
10
6 )
G
0 1 2 3 4
0.05
0.1
0.15
0.2
SIRT3 WT
SIRT3 KO
Day
C
el
l n
um
be
r (
x 
10
6 )
H I
PPP
PPP
E
SIRT3 WT SIRT3 KO
0.0
0.5
1.0
1.5
*
SIRT3 WT SIRT3 KO
0
1
2
3
**
R
el
at
iv
e 
gl
uc
os
e 
up
ta
ke
SIRT3 WT SIRT3 KO
0.0
0.5
1.0
1.5
2.0
**
R
el
at
iv
e 
la
ct
at
e 
pr
od
uc
tio
n
control rotenone
0
1
2
3
4
5
WT
KO
**
**
R
el
at
iv
e 
gl
uc
os
e 
up
ta
ke
control rotenone
0
1
2
3
4
WT
KO
**
**
R
el
at
iv
e 
la
ct
at
e 
pr
od
uc
tio
n
control etomoxir
0
1
2
3
4 WT
KO
**
**
R
el
at
iv
e 
gl
uc
os
e 
up
ta
ke
control etomoxir
0.0
0.5
1.0
1.5
2.0 WT
KO
**
**
R
el
at
iv
e 
la
ct
at
e 
pr
od
uc
tio
n
NK ML
G
lu
co
se
R
el
at
iv
e 
le
ve
ls
G
lu
co
se
-1
-p
ho
sp
ha
te
R
el
at
iv
e 
le
ve
ls
R
ib
os
e-
5-
ph
os
ph
at
e
R
el
at
iv
e 
le
ve
ls
Figure 1. Metabolic Profiles of SIRT3 KO MEFs Reflect an Increase in Glycolytic Pathways and a Decrease in Mitochondrial Oxidative
Metabolism
(A) Schematic illustrating themetabolites that are increased (red) or decreased (blue) in SIRT3 KOMEFs compared to SIRT3WTMEFs (n = 4; p < 0.1). Metabolites
in parentheses were not measured. The nonoxidative (red) and oxidative (black) arms of the PPP are shown. Levels of glycolytic intermediates (B), TCA cycle
intermediates (C), glucose (D), glucose-1-phosphate (E), and ribose-5-phosphate (F). Growth curves of SIRT3 WT and KO MEFs (n = 3) cultured in media
containing glucose (G) or galactose (H). Error bars, ±SD (I–N) Glucose uptake and lactate production in SIRT3WT and KOMEFs (n = 6). (I) Relative glucose uptake
and (J) lactate production in SIRT3WT and KOMEFs. (K) Relative glucose uptake and (L) relative lactate production in SIRT3WT and KOMEFs incubated with or
without 100 nM rotenone. (M) Glucose uptake and (N) lactate production in SIRT3 WT and KO MEFs cultured in the presence or absence of 50 mg/ml etomoxir.
Cells were treated with drugs for 24 hr before measuring glucose uptake and lactate. All error bars (except growth curves), ±SEM. *p < 0.05; **p < 0.01;
***p < 0.001. See also Figure S1.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1aStrikingly, glucose uptake and lactate production remain
elevated in the SIRT3 KO cells even in the presence of oxidation
inhibitors (Figures 1K–1N). These data demonstrate that upre-
gulated glycolysis in SIRT3 null cells does not result solely418 Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc.from nonspecific compensation for decreased mitochondrial
oxidative functions. Instead, these data indicate that, surpris-
ingly, SIRT3 may regulate glycolysis via activation of a specific
signaling pathway.
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Figure 2. SIRT3 KO Mice Have Elevated Glucose Uptake and Hypoxic Signatures In Vivo
18F-FDG uptake in the BAT of SIRT3 WT and KO mice was measured using PET/CT.
(A) Representative scans with color scale bar indicating relative levels of uptake from low (black) to high (white).
(B) Quantification of BAT 18F-FDG uptake normalized to body weight (n = 6).
(C) GSEA of canonical pathways with the ranked genes list from most upregulated to most downregulated in SIRT3 KO BAT.
(D) Heat map comparing metabolite patterns of SIRT3 deletion and hypoxia. Red and blue indicate up- or downregulation, respectively. SIRT3 WT and KOMEFs
(n = 4) were cultured in 21%O2 (normoxia, N) or 1%O2 for 12 hr (hypoxia, H), andmetabolites were analyzed by LC-MS. Relative levels of glycolytic intermediates
(E) and ribose-5-phosphate (F).
(G) Glucose uptake of MEFs cultured under hypoxia for 6 hr. Error bars, ±SEM. *p < 0.05; **p < 0.01.
See also Figure S2.
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SIRT3 Reprograms Cell Metabolism through HIF1aWe next asked whether SIRT3 KO mice exhibited signs of
increased glucose usage. We injected mice with 18F-fluorodeox-
yglucose (18F-FDG) and scanned animals using positron emis-
sion tomography-computed tomography (PET/CT) in order to
monitor glucose uptake. We looked specifically in brown
adipose tissue (BAT), which exhibits high glucose uptake
(Cannon and Nedergaard, 2004). In line with our cellular studies,
we found that SIRT3 KOmice had an increase in 18F-FDG uptake
in BAT comparedwithWTmice (Figures 2A and 2B), even though
the mass of BAT in SIRT3 KO mice was not larger than in WT
mice (Figure S2A). Glucose uptake in BAT is regulated by the
b-adrenergic pathway and is thus dramatically increased by
cold exposure (Shimizu et al., 1991). We measured 18F-FDG
uptake in BAT of SIRT3 WT and KO mice after a 6-hr cold chal-
lenge and found that SIRT3 KO mice have higher 18F-FDGuptake both at room temperature and at 4C (Figure 2B;
Figure S2B), illustrating that SIRT3 WT and KO mice have
a similar increase in BAT glucose uptake in response to b-adren-
ergic signaling. These differences in BAT glucose uptake occur
independently of obvious changes in whole-body glucose
homeostasis: we did not detect changes in blood glucose levels
(Figure S2C) as reported previously (Lombard et al., 2007).
To examinemechanisms underlying increased glucose uptake
in SIRT3 KO BAT, we performed genome-wide expression
profiling on RNA isolated from BAT and performed gene set
enrichment analysis (GSEA) using the ranked gene list from
most upregulated to most downregulated in SIRT3 KO mice in
order to identify the biological pathways most significantly
altered by SIRT3 loss. Because SIRT3 is a mitochondrial deace-
tylase, we expected to see compensatory upregulation ofCancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc. 419
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1apathways involving mitochondrial function or energy production.
To our surprise, SIRT3 loss upregulated pathways important in
tumorigenesis. Strikingly, of the nine gene sets most significantly
overrepresented in SIRT3 KO BAT, three were independently
defined as gene sets induced by exposure to hypoxia (Figure 2C;
Figure S2B). Hypoxia itself increases 18F-FDG uptake (Clavo
et al., 1995) and is associated with many transcriptional changes
that result in increased glucose uptake and utilization (Brahimi-
Horn et al., 2007). Thus, we hypothesized that the increase in
glucose uptake in SIRT3 KO BAT could be explained by upregu-
lation of the hypoxia response.
The similarity between gene signatures of SIRT3 KO mice and
hypoxic cells was particularly notable because hypoxia induces
a metabolic shift similar to that caused by loss of SIRT3,
including a decrease in mitochondrial substrate oxidation and
an increase in glycolysis (Semenza, 2010). To test the role of
SIRT3 in hypoxia-induced metabolic reprogramming, we
analyzed metabolites isolated from MEFs cultured at 21% O2
(normoxia) or 1% O2 (hypoxia) for 12 hr. Strikingly, we observed
that the increase in glycolytic intermediates caused by hypoxia
was similar to the effects of SIRT3 deletion (Figure 2D). Further-
more, hypoxia and SIRT3 loss had additive effects: whereas
intermediates of glycolysis, glycogenolysis, and the PPP were
elevated by hypoxia, levels of these metabolites were even
higher in SIRT3 KO MEFs under these conditions (Figures 2E
and 2F; Figure S2E). Consistent with the metabolite profiles,
hypoxia increased glucose uptake in both cell lines, and SIRT3
KO or knockdown cells consumed even more glucose than
control cells (Figure 2G; Figure S2F). Taken together, these
data illustrate that SIRT3 loss and hypoxia result in similar meta-
bolic shifts and implicate dysregulated activation of the hypoxia
pathway as a cause of the metabolic reprogramming of SIRT3
null cells.
SIRT3 Opposes the Warburg Effect
by Destabilizing HIF1a
HIF1, the heterodimer of HIF1a andHIF1b, is the primary driver of
increased glycolysis and lactate production during hypoxia (Gor-
dan and Simon, 2007; Hu et al., 2003; Seagroves et al., 2001).
Under conditions of low oxygen, HIF1a is stabilized and
promotes transcription of many genes crucial for the cellular
response to hypoxia (Kaelin and Ratcliffe, 2008). Consequently,
cells lacking HIF1a fail to upregulate glycolytic enzymes and
lactic acid production in response to hypoxia (Seagroves et al.,
2001). Given the in vivo hypoxic gene signature of SIRT3 null
BAT, in addition to the striking similarity between the mitochon-
drial-independent glycolytic profiles of SIRT3 KO MEFs and
hypoxic cells, we reasoned that the mechanism by which
SIRT3 regulates glycolysis involves HIF1a. To test this idea we
first investigated whether SIRT3 directly modulates HIF1a
stability under normoxic conditions. In the presence of high
oxygen, HIF1a is rapidly degraded and difficult to measure
from cell lysates, but HIF1a is detectable from isolated nuclei.
Indeed, nuclei isolated from SIRT3-deficient cells during nor-
moxia demonstrated elevated levels of HIF1a relative toWT cells
(Figure 3A). Likewise, when MEFs were cultured under 1% O2,
HIF1a was stabilized earlier and to a higher degree in SIRT3
KO cells compared to WT cells in whole-cell lysates (Figure 3B).
We obtained comparable results in HEK293T cells in which420 Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc.SIRT3 expression was stably reduced by lentiviral expression
of shRNA against SIRT3 (Figure 3C). Importantly, SIRT3 also
regulates expression of HIF1a target genes. Both the glucose
transporter Glut1 and hexokinase II (Hk2)—HIF1a target genes
that are critical for increased glucose uptake and catabolism
via aerobic glycolysis or the PPP and are strongly implicated in
tumorigenesis (O’Donnell et al., 2006; Tennant et al., 2010)—
were elevated during hypoxia in SIRT3 KO MEFs and SIRT3
knockdown cells relative to control cells (Figure 3D; Figure
S3A). Furthermore, the HIF1a targets pyruvate dehydrogenase
kinase 1 (Pdk1), lactate dehydrogenase A (Ldha), phosphoglyc-
erate kinase (Pgk1), and vascular endothelial growth factor A
(Vegfa) were significantly elevated in SIRT3 KO cells compared
to WT cells during hypoxia (Figure 3D). Similar to the pattern
we saw with metabolic intermediates of glycolysis, many of
these genes were moderately elevated by SIRT3 loss under
basal conditions (Figure S3B), and SIRT3 deletion and hypoxia
had additive effects on expression of HIF1a target genes
(Figure 3D).
To test whether SIRT3 directly represses HIF1a, we examined
the levels of HIF1a and its target genes in cells overexpressing
SIRT3. SIRT3 overexpression clearly and reproducibly reduced
the extent of HIF1a stabilization in hypoxic cells (Figure 3E).
Importantly, the induction of GLUT1 and HK2 during hypoxia
was blunted by SIRT3 overexpression, demonstrating that
SIRT3 directly inhibits HIF1a function (Figure 3F). SIRT3 catalytic
activity was required for the full repression of HIF1a target genes:
expression of a SIRT3 catalytic mutant did not significantly
reduce hypoxic GLUT1 expression (Figure S3C). Furthermore,
using primary MEFs, we found that two SIRT3 KO lines exhibited
increased Glut1 expression relative to two WT lines, suggesting
that SIRT3 can regulate HIF1a activity in primary cell lines (Fig-
ure S3D). Taken together, the data show that SIRT3 controls
the stabilization of HIF1a and the induction of crucial HIF1a
target genes that coordinate aerobic glucose consumption.
Next, to examine the requirement for HIF1a in the glycolytic
shift observed in SIRT3 null cells, we used two separate shRNA
constructs against HIF1a to generate SIRT3 WT and KO MEFs
with HIF1a levels stably reduced (Figure S3E).Wemeasured nor-
moxic and hypoxic Glut1 expression in these cell lines and
found, as predicted, that control (shNS) SIRT3 KOMEFs demon-
strated an exaggerated response to hypoxia, measured as the
fold change in Glut1 expression, compared to control WT
MEFs (Figure 3G). In contrast, WT and SIRT3 KOMEFs express-
ing either shRNA against HIF1a had comparable responses to
hypoxia (Figure 3G; Figure S3F). Importantly, the increase in
lactate production caused by SIRT3 deletion required HIF1a
both in normoxia and hypoxia (Figure 3H; and Figure S3G).
Together, these data demonstrate that SIRT3 regulates aerobic
glycolysis through HIF1a.
To probe for evidence of increased HIF1a activation in vivo, we
measured levels of HIF1a and HIF1a target genes from tissues of
SIRT3WT and KOmice. Levels of HIF1a protein andmany HIF1a
target genes involved in glycolysis were significantly elevated in
the BAT of SIRT3 KO mice (Figure 3I; Figure S3H–S3J), consis-
tent with our studies demonstrating increased glucose uptake
in SIRT3 KO BAT. Similarly, several HIF1a target genes showed
a trend of increased expression in SIRT3 KO heart (Figure 3I;
Figure S3K).
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Figure 3. SIRT3 Regulates HIF1a Stability
(A) Immunoblots of nuclear extracts from SIRT3 WT and KO MEFs cultured at 21% O2.
(B and C) Immunoblots of MEFs (B) or HEK293T cells expressing control shRNA (shNS) or shRNA targeted against SIRT3 (C) cultured at 1% O2 for the indicated
times.
(D) HIF1a target genes in SIRT3 WT and KO MEFs after 6 hr of hypoxia were measured by qRT-PCR and shown as a ratio of SIRT3 WT normoxia levels.
(E) Immunoblots of HEK293T cells stably overexpressing empty vector or SIRT3 cultured at 1% O2 for the indicated times.
(F) Expression of HIF1a target genes in HEK293T control and SIRT3-overexpressing cells after 6 hr of hypoxia.
(G) SIRT3WT andKOMEFs expressing shNS or shRNA against HIF1a (shHIF1#1,2) were cultured in normoxia or hypoxia (6 hr), and the fold change inGlut1 levels
was measured by qRT-PCR.
(H) Lactate produced by SIRT3 WT and KO MEFs expressing shNS or shHIF1a after 6 hr of hypoxia expressed as a ratio of SIRT3 WT shNS normoxic controls.
Significance was assessed by two-way ANOVA.
(I) Expression ofGlut1 and Hk2 in the BAT (left) and heart (right) of SIRT3 WT and KOmice (n = 5–7) was measured by qRT-PCR. b-2-Microglobulin or Rps16 was
used as an endogenous control for qRT-PCR. Error bars, ±SEM (n = 4–6). *p < 0.05; **p < 0.01.
See also Figure S3.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1aThe regulation of HIF1a is complex and not completely under-
stood (Kaelin and Ratcliffe, 2008). During normoxia, HIF1a is
hydroxylated at two proline residues by a family of oxygen-
dependent prolyl hydroxylases (PHD1–3), enabling the tumor
suppressor von Hippel-Lindau (vHL) to bind and target HIF1a
for ubiquitination and proteasomal degradation (Kaelin and Rat-
cliffe, 2008). Because we did not detect changes in HIF1amRNA
levels (Figures 3D and 3F), we tested whether SIRT3 exerted
a posttranslational effect on HIF1a stability. SIRT1 binds HIF1a
and regulates its activity through direct deacetylation (Lim
et al., 2010). To test whether SIRT3 might act through a similar
mechanism,we immunoprecipitated SIRT1 or SIRT3 and probedfor interactions with HIF1a. SIRT1, but not SIRT3, pulled down
HIF1a (Figure S4A), suggesting that SIRT3 does not interact
with HIF1a directly.
We next tested the hypothesis that SIRT3 regulates HIF1a
stability by modulating PHD activity by measuring the extent of
HIF1a hydroxylation. We assessed PHD activity in control and
SIRT3 knockdown HEK293T cells by treating cells with the pro-
teasomal inhibitor MG-132 (to prevent hydroxylated HIF1a from
being degraded) or with dimethyloxalylglycine (DMOG; to inhibit
PHDs). Although SIRT3 knockdown cells accumulated more
HIF1a during MG-132 treatment, they had significantly less
hydroxylated HIF1a, indicating that PHD activity is lower inCancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc. 421
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Figure 4. SIRT3 Regulates HIF1a Stability through ROS
(A) Nuclear extracts from shNS and shSIRT3 HEK293T cells treated with or without 10 mM MG-132 for 1 hr or 1 mM DMOG for 4 hr as indicated were immuno-
blotted with antibodies specific to hydroxylated HIF1a (HIF-OH) or total HIF1a.
(B) Fold induction of HIF1a target genes in response to hypoxia (n = 6) measured by qRT-PCR. The ratio of hypoxic to normoxic gene expression is shown.
(C) Fold induction ofGlut1 and Hk2 in response to DMOG treatment was measured by qRT-PCR, and the ratio of untreated to DMOG-treated gene expression is
shown (n = 6).
(D) The increase in ROS production with hypoxia was calculated as the fold change in ROS in hypoxic cells relative to normoxic controls.
(E) Immunoblots of SIRT3 WT and KO MEFs incubated with 10 mM NAC and cultured under normoxia or hypoxia.
(F) Immunoblots of SIRT3 WT and KO MEFs cultured at 21% O2 with 10 mM NAC or 1 mM DMOG as indicated.
(G) Glut1 expression was measured by qRT-PCR in SIRT3 WT and KO MEFs (n = 5) that were incubated with 10 mM NAC and cultured under hypoxia. Signif-
icance was assessed by one-way ANOVA.
(H) Growth curves of SIRT3 WT and KO MEFs (n = 3) cultured in standard media or media supplemented with 10 mM NAC. Error bars, ±SD.
(I and J) Protein carbonyls (I) and lipid peroxidation (J) were measured in BAT of SIRT3 WT and KO mice (n = 7).
(K) qRT-PCR analysis of Glut1 expression in BAT of SIRT3 WT and KO mice treated with 40 mM NAC. b-2-Microglobulin or Rps16 was used as an endogenous
control. Error bars (except for growth curves), ±SEM. ns, nonsignificant. *p < 0.05; **p < 0.01.
See also Figure S4.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1aSIRT3 knockdown cells (Figure 4A). Similarly, SIRT3 WT MEFs
demonstrated higher levels of HIF1a hydroxylation than KO
MEFs (Figure S4B). If SIRT3 influences HIF1a stability through
modulation of PHD activity, then treatment with the potent
PHD inhibitor DMOG would overcome the effects of SIRT3 dele-
tion and result in equivalent levels of HIF1a stabilization in SIRT3
WT and KO cells. Indeed, we observed that at every time point
examined, SIRT3 WT and KO MEFs have equal levels of HIF1a
stabilized in response to DMOG treatment (Figure S4C).
To confirm that SIRT3 influences HIF1a through the PHDs, we
performed a series of experiments comparing the effects of
hypoxia and DMOG treatment on SIRT3 WT and KO MEFs. We
observed that both hypoxia and DMOG stabilize HIF1a and
induce expression of HIF1a target genes (Figures 4B and 4C).422 Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc.The relative responses of SIRT3 WT and KO MEFs to hypoxia
and DMOG underscore the PHDs as the point of regulation by
SIRT3. During hypoxia, HIF1a target genes are induced more
strongly in SIRT3 KO cells, illustrating the physiological impor-
tance of SIRT3 in regulating the metabolic response to hypoxia
(Figure 4B). In contrast, SIRT3 deletion represses the induction
of HIF1a target genes in response to DMOG (Figure 4C). These
data support a model whereby PHD activity is already reduced
in SIRT3 KO cells. Consequently, when PHD activity is potently
blocked by DMOG, SIRT3 KO cells have a smaller change in
PHD activity and, thus, a smaller induction of HIF1a target genes.
Together, these results point to reduced PHD activity as the
mechanism of increased HIF1a expression in SIRT3-deficient
cells.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1aSeveral intracellular signals, in addition to changes in oxygen
concentration, are known to regulate PHD activity. Notably,
ROS have been shown to inhibit the PHDs and stabilize HIF1a
(Gerald et al., 2004; Kaelin and Ratcliffe, 2008). Moreover,
hypoxia triggers an increase in ROS production that is required
for the hypoxic activation of HIF1a (Chandel et al., 1998; Hama-
naka and Chandel, 2009). Because SIRT3 is a well-known inhib-
itor of ROS (Kawamura et al., 2010; Kim et al., 2010; Kong et al.,
2010; Sundaresan et al., 2009), we hypothesized that increased
ROS in SIRT3-deficient cells would contribute to the inhibition of
the PHDs. Thus, we tested whether SIRT3 loss would magnify
the increase in ROS associated with hypoxia. We found
that the hypoxia-triggered increase in ROS was significantly
higher in SIRT3 KO MEFs (Figure 4D), providing a mechanistic
explanation for why SIRT3 null cells have an exaggerated
response to hypoxia.
Next, we treated cells with the antioxidant N-acetylcysteine
(NAC) in order to probe the model that suppressing ROS could
block the effects of SIRT3 deletion. Indeed, we observed that
whereas SIRT3 KO MEFs had higher levels of HIF1a during
hypoxia, NAC treatment reduced HIF1a to comparable levels
in SIRT3 WT and KO MEFs (Figure 4E). In contrast, SIRT3 WT
and KO MEFs have comparable levels of HIF1a induced by
DMOG (Figure 4F), and NAC could no longer destabilize HIF1a
in the presence of DMOG (Figure 4F; Figure S4D). As predicted
by the decrease in HIF1a observed in NAC-treated KO MEFs,
NAC treatment restored Glut1 expression in KO MEFs to WT
levels (Figure 4G). Finally, to test whether increased ROS could
underlie the proliferative phenotype of SIRT3 KO MEFs, we
cultured cells with NAC and measured growth rates. Strikingly,
we found that NAC rescued the increased proliferation of
SIRT3 KO MEFs, restoring their growth to WT levels (Figure 4H).
Thus, regulation of ROS by SIRT3 plays an important role in
stabilization of HIF1a and activation of glycolytic metabolism in
SIRT3 null cells.
To examine the contribution of increased ROS to altered BAT
metabolism in vivo, we first looked for evidence of increased
ROS in SIRT3 KO tissues. We found that two measures of oxida-
tive damage, protein carbonyls and lipid peroxidation, were
significantly elevated in SIRT3 KO BAT (Figures 4I and 4J).
Because antioxidant treatment rescued the HIF1a-driven gene
expression in cultured cells, we hypothesized that NAC treat-
ment would reverse the glycolytic signature in SIRT3 KO tissues.
To test this idea we treated mice with NAC for 1 month and
measured expression of HIF1a target genes in BAT. Strikingly,
we found that NAC repressed expression of HIF1a target genes
in SIRT3 KO mice, but not in SIRT3 WT mice (Figure 4K; Figures
S4E and S4F). These data demonstrate that increased ROS
production in vivo contributes to enhanced glycolytic gene
expression in SIRT3-deficient mice.
SIRT3 Loss Increases Glycolytic Signatures in Tumors
HIF1a activity and aerobic glycolysis are strongly implicated in
the Warburg effect (Semenza, 2010), and so we reasoned that
SIRT3 may exert its tumor-suppressive activity by opposing
the HIF1a-mediated activation of the Warburg effect. Previously,
SIRT3 deletion was shown to increase colony formation in a soft
agar colony growth assay (Kim et al., 2010). To investigate the
contribution of HIF1a to this tumorigenic phenotype, we trans-formed primaryMEFs by expressing the Ras and E1a oncogenes
and then stably knocked down HIF1a. As previously shown (Kim
et al., 2010), we found that SIRT3 loss increased colony forma-
tion (Figure 5A). Importantly, knock down of HIF1a rescued the
increased colony formation of SIRT3 KO cells (Figure 5A).
Furthermore, SIRT3 WT and KOMEFs formed colonies at equiv-
alent rates when cultured in media containing galactose instead
of glucose (Figure S5A), suggesting that colony formation
required glucose metabolism. Taken together, these data
suggest that the metabolic reprogramming mediated by SIRT3
via HIF1a could be an important contributor of the tumor-
suppressive role of SIRT3.
Next, we performed xenograft assays with the transformed
MEFs in order to probe the metabolic status of SIRT3 null
tumors. As has previously been shown (Kim et al., 2010), we
found that tumors lacking SIRT3 had a growth advantage:
tumors formed from 64% of KO injections, but only 27% of WT
injections and tumors lacking SIRT3 grew faster and were bigger
thanWT tumors (Figures S5B–S5F). Because tumors are subject
to intermittent hypoxia (Gatenby and Gillies, 2004), we examined
expression of rate-limiting glycolytic genes in the xenograft
tumors. Strikingly, HIF1a target genes were elevated in SIRT3
KO tumors (Figure 5B); SIRT3 KO tumors also showed higher
levels of GLUT1 protein (Figure 5C). Taken together, these
data suggest that increased levels of glycolytic enzymes,
perhaps as part of a heightened response to hypoxia, provide
a growth advantage for tumor cells lacking SIRT3 in vivo.
SIRT3 Is Deleted in Many Human Cancers
Our data indicate that SIRT3may regulate tumor cell metabolism
and anabolic growth pathways. In order to determine the rele-
vance of SIRT3 in human cancers, we first examined the copy
number variations of SIRT3 that are associated with the progres-
sion of multiple types of human cancer (Beroukhim et al., 2010).
Strikingly, at least one copy of the SIRT3 gene is deleted in 20%
of all human cancers and 40% of breast and ovarian cancers
present in the data set (Figure 5D). SIRT3 is significantly focally
deleted (deletions of less than a chromosome arm) across all
cancers, and focal deletions of SIRT3 were especially frequent
in breast and ovarian tumors (Figure 5D). In contrast, SIRT4
and SIRT5 were not significantly focally deleted in any of the
14 subtypes analyzed (Figure 5E; data not shown). TP53, a tumor
suppressor known to be frequently deleted in many human
cancers, is included as a control (Fisher, 2001) (Figure 5E;
Figures S4G and S4H). Our analysis of copy number changes
at the SIRT3 locus revealed no evidence of focal amplifications
across 14 types of cancer. Most of the genomic SIRT3 deletions
are heterozygous, and SIRT3 deletion frequencies are similar to
the well-known breast cancer tumor suppressors, BRCA1 and
BRCA2, which are heterozygously deleted in 43% and 40% of
human breast cancers, respectively (data not shown). Intrigu-
ingly, the peak region of deletion that includes SIRT3 (11p15.5)
does not contain any known tumor suppressor (Beroukhim
et al., 2010).
Because breast cancers exhibited exceptionally high
frequency of SIRT3 deletions compared to other tumor types
(Figure 5D) (Kim et al., 2010), we further examined SIRT3 in
human breast cancers. Elevated HIF1a expression in breast
carcinomas is associated with tumor aggressiveness and poorCancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc. 423
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Figure 5. SIRT3 Is Significantly Deleted in Human Breast Cancer
(A) Soft agar assays using transformed SIRT3 WT and KO MEFs expressing shNS or shRNA against HIF1a (shHIF1) (n = 4).
(B) Quantitative RT-PCR on RNA isolated from xenograft tumors and normalized to expression of 36B4.
(C) H&E (left) and immunohistochemical analysis of GLUT1 expression (right) in xenograft tumors. One representative pair of contralateral tumors is shown. Scale
bar, 50 mm.
(D) Table summarizing SIRT3 deletion frequency across a panel of human tumors.
(E) Schematic of copy number changes at the SIRT3-5 and TP53 loci. Amplifications are shown in red; deletions are shown in blue.
(F) Expression levels of SIRT3 and several HIF1a target genes were determined using the Oncomine cancer microarray database (http://www.oncomine.org) in
normal versus breast cancers.
(G) Linear regression of SIRT3 and GLUT1 across the panel of normal and breast cancer samples described in (F).
(H) Representative image of SIRT3 expression in normal breast epithelium and in breast tumor cells as assessed by immunohistochemistry. SIRT3 levels were
classified as absent (0), weak scattered (1), or positive as strong (2) compared to normal epithelium, and the percentage of patients classified in each category is
depicted in histogram at right. Error bars, ±SEM (n = 4–6). *p < 0.05; **p < 0.01.
See also Figure S5.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1aprognosis (Chaudary and Hill, 2006). Many breast cancer cells
exhibit increased glycolysis, and expression of GLUT1 is a char-
acteristic feature of many breast cancer biopsies (Rivenzon-
Segal et al., 2003). In xenograft models, SIRT3 loss increases
expression of HIF1a target genes and results in strong GLUT1
expression (Figures 5B and 5C). Thus, we looked for a relation-
ship between SIRT3 loss and HIF1a targets in human breast
cancer. Gene expression profiling of seven normal breast
samples and 40 ductal breast carcinomas revealed that SIRT3
expression is significantly reduced (p = 3.53e-8) in breast carci-
nomas (Richardson et al., 2006) (Figure 5F). Moreover, several
HIF1a target genes—most notably GLUT1—were significantly
increased in the same data set (Figure 5F). We further analyzed424 Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc.the correlation between SIRT3 and GLUT1 expression in indi-
vidual samples from this data set and found that SIRT3 is signif-
icantly inversely correlated with GLUT1 (p = 0.0008) (Figure 5G).
Our results demonstrate that SIRT3 loss is associated with
increased expression of HIF1a target genes in vivo and in human
breast cancer and provide a metabolic link between SIRT3 dele-
tion and breast cancer tumorigenesis.
To confirm that SIRT3 expression is reduced in human breast
cancers, we analyzed SIRT3 protein levels by immunohisto-
chemistry in normal breast epithelium in addition to a large panel
of human breast cancer tissue. Out of 46 patient samples, only
six demonstrated SIRT3 staining that was positive or as strong
as SIRT3 staining in normal epithelium (Figure 5H). Strikingly,
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1a87%of patients showed decreased or undetectable SIRT3 stain-
ing in adjacent cancer tissue, and 20% of patients showed no
detectable SIRT3 (Figure 5H). Similarly, gene expression
profiling of an independent set of human breast cancer samples
(Richardson et al., 2006) revealed that 25% of breast cancers
exhibited at least a 6-fold reduction in the mRNA of SIRT3
compared to normal breast epithelium (Figure S5I). This inde-
pendent data set provides additional validation for the observa-
tion that SIRT3 is deleted in human tumors (Figure 5D) (Berou-
khim et al., 2010). Furthermore, an earlier high-resolution
analysis of copy number variation in 171 human breast tumors
similarly found significant reduction in SIRT3 copy number
(Chin et al., 2007). These findings also support those of Kim
et al. (2010), who first reported that SIRT3 KO mice develop
mammary tumors and that SIRT3 levels were decreased in
human breast cancer.
The studies of SIRT3 expression in human cancers suggest
that SIRT3 may function as a tumor suppressor in part by pre-
venting the metabolic shift that facilitates tumor growth. In order
to examine whether SIRT3 can actively repress the Warburg
effect in tumor cells, we stably overexpressed SIRT3 in three
independent breast cancer cell lines: MCF7, T47D, and
CAMA1 (Figure S6A). We analyzed the glucose uptake and
lactate secretion in cells during hypoxia in order to simulate the
tumor microenvironment. We found that SIRT3 repressed both
lactate production and glucose uptake in every cell line tested
(Figures 6A and 6B). These data clearly demonstrate that overex-
pression of SIRT3 in tumor cells is sufficient to reverse the meta-
bolic shift associated with the Warburg effect.
Because SIRT3 robustly suppressed glucose uptake and
lactate production in the CAMA1 cells, we chose to further
analyze these cell lines. To examine the contribution of complex
I activity or fatty acid oxidation on these phenotypes, we
measured glucose uptake and lactate production in the pres-
ence of rotenone and etomoxir. Both rotenone and etomoxir
increased glucose uptake and lactate production to a similar
degree in both control and SIRT3-overexpressing cell lines, indi-
cating that the repression of glycolysis by SIRT3 is independent
of the influence of SIRT3 on fatty acid oxidation or complex I
activity (Figures 6C–6F).
We next examined whether SIRT3 repressed HIF1a in CAMA1
cells. SIRT3 overexpression strongly reduced HIF1a protein
levels and expression of HIF1a target genes in hypoxic cells
(Figures 6G and 6H). Moreover, when we examined the fold
change of HIF1a targets in response to hypoxia or DMOG treat-
ment, we found the inverse of the results using SIRT3 KOMEFs.
SIRT3overexpression blunted the response to hypoxia (Figure 6I)
while increasing the response to DMOG (Figure 6J). This is
consistent with a model of elevated PHD activity in SIRT3-over-
expressing cells and illustrates the importance of SIRT3 in regu-
lating the physiological response to hypoxia at the level of the
PHDs.
Next, we tested the hypothesis that SIRT3-mediated control
of glucose metabolism could influence cancer cell proliferation.
SIRT3 overexpression significantly repressed proliferation of
CAMA1 cells cultured in high glucose (Figure 6K). Remarkably,
control and SIRT3-expressing cells proliferated at similar rates
when cultured in media containing galactose instead of glucose
(Figure 6L). These data illustrate that SIRT3 regulates cancercell growth by influencing the use of glucose for anabolic
processes.
DISCUSSION
In this study we demonstrate that SIRT3 regulates cellular
metabolism through HIF1awith important implications for tumor
cell growth. Previously, it has been shown that SIRT3 is a mito-
chondrial deacetylase that activatesmultiple metabolic enzymes
and promotes mitochondrial substrate oxidation and ATP
production (Finkel et al., 2009; Verdin et al., 2010). Our study
shows that SIRT3 additionally controls glycolytic metabolism
(Figures 1 and 2) by regulating the stability and activity of
HIF1a (Figure 3). We find that elevated ROS in SIRT3 null cells
contributes to increased HIF1a stabilization and activity (Fig-
ure 4). Significantly, loss of SIRT3 in human tumor samples
correlates with glycolytic gene expression, highlighting the
potential importance of SIRT3-mediated metabolic reprogram-
ming in human cancers (Figure 5). This idea is further validated
by the finding that SIRT3 represses the Warburg effect in human
breast cancer cell lines (Figure 6). Taken together, these data
provide a mechanism whereby SIRT3 functions as a tumor
suppressor by regulating glycolytic and anabolic metabolism
(Figure 6M).
Our findings are consistent with previous work showing that
SIRT3 functions as a tumor suppressor through regulation of
ROS (Kim et al., 2010). Kim et al. (2010) found that elevated
ROS in the absence of SIRT3 increased genomic instability,
promoting a tumor-permissive environment. We propose that
SIRT3 loss and increased ROS also promote tumorigenesis by
altering global cellular metabolism. In this study we demonstrate
that elevated ROS stabilizes HIF1a, increasing glucose uptake
and catabolism and, thus, providing the metabolic precursors
necessary to fuel a high rate of proliferation. Importantly, we
demonstrate that increased glycolysis is not simply compensa-
tion for reduced mitochondrial oxidative capacity. Rather,
SIRT3 actively regulates cellular glucose metabolism by acti-
vating a specific signaling node (Figures 1K–1N and 6C–6F).
Thus, taken together, our study and the one by Kim et al.
(2010) show that SIRT3 loss results in a double-edged sword
for tumor cells—creating an environment of increased genome
instability as well as HIF1a activation, enabling increased glycol-
ysis and cellular growth.
Recent studies have shed light on the mechanism through
which SIRT3 regulates cellular ROS. Several groups have
provided evidence that SIRT3 can influence transcription of anti-
oxidant genes through activation of FoxO3a (Kim et al., 2010;
Sundaresan et al., 2009), although we did not find a difference
in Sod2 expression under our culture conditions (Figure S6B).
Additionally, SIRT3 can directly target IDH2, influencing cellular
redox status, and SOD2, activating mitochondrial ROS scav-
enging (Qiu et al., 2010; Someya et al., 2010; Tao et al., 2010).
As a result, SIRT3 can directly influence mitochondrial metabo-
lism and ROS generation through deacetylation of multiple
substrates. At the same time the ROS by-product of reduced
SIRT3 activity acts as a retrograde signal to reprogram cellular
metabolism.
Our studies reveal the profound impact of SIRT3 function on
glycolysis and tumor cell metabolism. SIRT3 appears to beCancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc. 425
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Figure 6. SIRT3 Suppresses the Warburg Effect in Human Breast Cancer Cells
(A) Lactate production and (B) glucose consumption of MCF7, T47D, and CAMA1 cells stably expressing empty vector or SIRT3 and cultured under hypoxia
expressed as a ratio of empty vector-normoxic controls.
(C) Relative glucose uptake and (D) relative lactate production in CAMA1 control or SIRT3-overexpressing cells incubated with or without 100 nM rotenone.
(E) Glucose uptake and (F) lactate production in CAMA1 cell lines cultured in the presence or absence of 50 mg/ml etomoxir.
(G) Immunoblots of CAMA1 cells stably expressing control vector or SIRT3-FLAG cultured at 1% oxygen for the indicated times.
(H) qRT-PCR of HIF1a target genes in CAMA1 cells cultured at 1% oxygen.
(I) Induction of HIF1a target genes in response to hypoxia measured by qRT-PCR in CAMA1 cells. The ratio of normoxic to hypoxic gene expression in each cell
line is shown.
(J) Induction of HIF1a target genes in response to 1 mM DMOG treatment measured by qRT-PCR in CAMA1 cells. The ratio of untreated to DMOG-treated gene
expression in each cell line is shown.
(K and L) Growth curves of CAMA1 cells (n = 3) cultured in glucose (K) or galactose (L). Error bars, ±SD. (M) Schematic of the regulation of HIF1a and theWarburg
effect by SIRT3. b-2-Microglobulin was used as an endogenous control for qRT-PCR. Error bars (except for growth curves), ±SEM. *p < 0.05; **p < 0.01.
See also Figure S6.
Cancer Cell
SIRT3 Reprograms Cell Metabolism through HIF1adecreased in human breast cancers (Figure 5) (Beroukhim et al.,
2010; Chin et al., 2007; Kim et al., 2010; Richardson et al., 2006).
It will be important for future work to examine the impact of
SIRT3 on each stage of tumorigenesis in mechanistic detail.
Given the function of SIRT3 in breast cancer (Kim et al., 2010),
in addition to our findings that SIRT3 can reprogram cellular
metabolism (Figures 1 and 2), we propose that the glycolytic
switch evident in cells lacking SIRT3will contribute to tumorigen-426 Cancer Cell 19, 416–428, March 15, 2011 ª2011 Elsevier Inc.esis, particularly in breast cancers. In support of this idea, we
show that SIRT3 can directly repress the Warburg effect in three
independent breast cancer cell lines (Figure 6). In sum, our
studies illustrate that SIRT3 functions as a tumor suppressor,
in part by regulating cellular metabolism through HIF1a. These
findings suggest that the regulation of tumor cell metabolism
by SIRT3 could provide an important area for cancer diagnosis
or therapeutic intervention.
Cancer Cell
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Metabolite Profiling
Metabolites were extracted in ice-cold methanol, and endogenous metabolite
profiles were obtained using two liquid chromatography-tandem mass spec-
trometry (LC-MS) methods as described (Luo et al., 2007). Data were acquired
using a 4000 QTRAP mass spectrometer (Applied Biosystems/Sciex). Multi-
Quant software (Applied Biosystems/Sciex) was used for analysis. Metabolite
levels were normalized to protein content, which was determined by perform-
ing a Bradford assay (Bio-Rad) on a duplicate set of cells treated identically to
the experimental cells.
Lactate and Glucose Measurements
Glucose and lactate levels in culturemedia weremeasured using the BioProfile
FLEX analyzer (Nova Biomedical) and normalized to cell number or using
the Lactate Reagent Kit (Trinity Biosciences). Fresh media were added to
a 6-well plate of subconfluent cells, and lactate concentration in the media
wasmeasured 30–60 min (Lactate Reagent Kit) or 6–24 hr (BioProfile Analyzer)
later and normalized to the number of cells in each well.
ROS Measurement
Cellular ROS was measured according to published protocols (Eruslanov and
Kusmartsev, 2010). Briefly, cells were washed with PBS and incubated with 5
mM CM-H2DCFDA (Invitrogen) for 30 min. Cells were trypsinized, and mean
FL1 fluorescence was measured by flow cytometry.
Oxidative Damage
Protein carbonyl content was determined as previously described (Levine
et al., 1994). Levels of lipid peroxidation were determined using a modified
version of the thiobarbituric acid reactive substances (TBARS) procedure (Ern-
ster et al., 1968).
Animal Studies
Animal studieswere performed according to protocols approved by the Institu-
tional Animal Care and Use Committee, the Standing Committee on Animals at
Harvard. Male 129Sv SIRT3 WT and KO (Lombard et al., 2007) littermates (a
generous gift from Dr. Fred Alt) fed a normal chow diet (PicoLab Diet 5053)
were used for all studies. PET/CT studies were performed at the Longwood
SAIF (Boston). Eight to 10-month-old male mice were injected with 300 mCi
18F-FDG and imaged 1 hr later on PET/CT. For cold challenge, mice were
injected after 6 hr at 4C. Results were analyzed using InVivoScope software.
For NAC studies, drinking water was supplemented with 40 mM NAC for
4 weeks prior to sacrifice. For xenograft studies, 5 3 106 or 7.5 3 106 SIRT3
WT or KO MEFs transformed by expression of the Ras and E1a oncogenes
were mixed with Matrigel (BD Biosciences) and injected subcutaneously into
nudemice (6- to 9-week-old males; Taconic Farms). Each mouse was injected
with WT cells on one flank and KO cells on the other flank. Tumor size was
measured every 2days, and tumorswere dissected andweighed after 4weeks.
Immunohistochemistry
Tumors were fixed in 4% paraformaldehyde and embedded in paraffin.
Sections were stained with hematoxylin and eosin (H&E) in accordance with
standard procedures. Immunohistochemistry was performed using antibodies
against GLUT1 (Alpha Diagnostic) according to manufacturer instructions. A
tissue microarray (TMA) was constructed as previously published using a fully
automated Beecher Instrument, ATA-27. The study cohort comprised of
breast carcinoma, consecutively ascertained at the Memorial Sloan-Kettering
Cancer Center (MSKCC) between 1993 and 2005. Use of tissue samples was
approved with an Institutional Review Board Waiver, and samples were de-
identified prior to analysis. All breast cancer biopsies were evaluated at
MSKCC, and the histological diagnosis was based on H&E. One to several
cores contained normal breast duct epithelium. The TMA was stained with
an antibody against SIRT3 (Cell Signaling) with pretreatment conditions
including citrate buffer and microwave at 1:100 dilution. Cores were scored
by a pathologist (J.T.-F.), and tumor staining intensity was compared to normal
breast duct epithelium as: 0, tumor showing no staining; 1, tumor weaker than
normal epithelium; and 2, tumor of equal or stronger intensity compared to
normal ductal epithelium (Figure S5J). Histologic immunohistochemicalimages for Figure 5H were obtained with the Olympus AH2 Microscope
Camera from Center Valley, PA. Image acquisition and processing software
were performed using an Olympus DP12 camera and software, and Adobe
Photoshop 7.0. Magnification was 3400 (scale bar 30 mm).
Statistics
Unpaired two-tailed Student’s t tests were performed unless otherwise noted.
All experiments were performed at least two to three times.
ACCESSION NUMBERS
The SIRT3 BATmicroarray has been deposited in a GEO database with acces-
sion number GSE27309.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at doi:10.1016/j.ccr.
2011.02.014.
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